Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance

NCT ID: NCT01788449

Last Updated: 2013-02-13

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 335 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2005-05-31
• Study Completion Date: 2007-02-28

Brief Summary

Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.

Detailed Description

Primarily, this study is designed to assess the efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of extended-spectrum betalactamases (ESBLs) producing E.coli or K pneumoniae, S aureus methicillin resistant (MRSA) and Enterococcus vancomycin resistant (VRE). Secondly, this study plans to determine the acquisition rate of ESBL producing E Coli or K pneumoniae, methicillin resistant S Aureus (MRSA) and vancomycin resistant Enterococcus spp (VRE), both pre- and post-intervention.

Conditions

Bacterial Infections

Study Design

• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

All patients admitted in ICU will be enrolled (who qualify for treatment).

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Monitor

Role: STUDY_DIRECTOR

Wyeth is now a wholly owned subsidiary of Pfizer

Other Identifiers

0910X-101852

Identifier Type: -

Identifier Source: org_study_id